Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting epigenetic modulators using PROTAC degraders: Current status and future perspective
Thomas Webb, Conner Craigon, Alessio Ciulli
Bioorganic & Medicinal Chemistry Letters (2022) Vol. 63, pp. 128653-128653
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
Ming He, Chao-Guo Cao, Zhihao Ni, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 165
Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications
Qian Zhong, Xina Xiao, Yijie Qiu, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 114
PROTAC degraders as chemical probes for studying target biology and target validation
Václav Nêmec, Martin P. Schwalm, Susanne Müller, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 18, pp. 7971-7993
Closed Access | Times Cited: 51
PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies
Nuwayo Ishimwe Sincere, Krishnan Anand, Sumel Ashique, et al.
Molecules (2023) Vol. 28, Iss. 10, pp. 4014-4014
Open Access | Times Cited: 37
Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods
Barmak Mostofian, Holli‐Joi Martin, Asghar M. Razavi, et al.
Journal of Chemical Information and Modeling (2023) Vol. 63, Iss. 17, pp. 5408-5432
Open Access | Times Cited: 27
Proteolysis Targeting Chimera Degraders of the METTL3–14 m6A-RNA Methyltransferase
Francesco Errani, Annalisa Invernizzi, Marcin Herok, et al.
JACS Au (2024) Vol. 4, Iss. 2, pp. 713-729
Open Access | Times Cited: 14
Degraders in epigenetic therapy: PROTACs and beyond
Xing‐Jie Dai, Shi‐Kun Ji, Meng‐Jie Fu, et al.
Theranostics (2024) Vol. 14, Iss. 4, pp. 1464-1499
Open Access | Times Cited: 11
Epigenomic heterogeneity as a source of tumour evolution
Marthe Laisné, Mathieu Lupien, Céline Vallot
Nature reviews. Cancer (2024)
Closed Access | Times Cited: 8
An updated patent review of BRD4 degraders
Zonghui Ma, Cun Zhang, Andrew A. Bolinger, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 10, pp. 929-951
Closed Access | Times Cited: 6
PROTAC: targeted drug strategy. Principles and limitations
O. A. Koroleva, Yu. V. Dutikova, A.V. Trubnikov, et al.
Russian Chemical Bulletin (2022) Vol. 71, Iss. 11, pp. 2310-2334
Open Access | Times Cited: 23
Workflow for E3 Ligase Ligand Validation for PROTAC Development
Nebojša Miletić, Janik Weckesser, Thorsten Mosler, et al.
ACS Chemical Biology (2025)
Open Access
Recent advances in PROTAC-based antiviral and antibacterial therapeutics
Can Zhou, Shiwei Yang, Jun Wang, et al.
Bioorganic Chemistry (2025), pp. 108437-108437
Closed Access
Discovery of the First-in-class DOT1L PROTAC Degrader
Hyerin Yim, Renhong Sun, Zhongli Xu, et al.
European Journal of Medicinal Chemistry (2025), pp. 117595-117595
Closed Access
Chemically induced degradation of epigenetic targets
Md Kabir, Xufen Yu, H. Ümit Kanıskan, et al.
Chemical Society Reviews (2023) Vol. 52, Iss. 13, pp. 4313-4342
Open Access | Times Cited: 12
Discovery of Potent and Selective G9a Degraders for the Treatment of Pancreatic Cancer
Yunkai Shi, Qianqian Shen, Ruikai Long, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 15, pp. 13271-13285
Closed Access | Times Cited: 4
A comprehensive review of BET-targeting PROTACs for cancer therapy
Xiaoli Zhou, Fang Zhao, Yong-Tao Xu, et al.
Bioorganic & Medicinal Chemistry (2022) Vol. 73, pp. 117033-117033
Closed Access | Times Cited: 17
Bifunctional robots inducing targeted protein degradation
M. Elizabeth Sobhia, Harish Kumar, Sonia Kumari
European Journal of Medicinal Chemistry (2023) Vol. 255, pp. 115384-115384
Closed Access | Times Cited: 7
PROTACs targeting epigenetic proteins
Chao Zhang, Yuna He, Xiuyun Sun, et al.
Acta Materia Medica (2023) Vol. 2, Iss. 4
Open Access | Times Cited: 7
Cancer epigenetic therapy: recent advances, challenges, and emerging opportunities
Rajita Vatapalli, Alex P. Rossi, Ho Man Chan, et al.
Epigenomics (2024), pp. 1-16
Open Access | Times Cited: 2
Integrating epigenetics and metabolomics to advance treatments for pulmonary arterial hypertension
A. Dushani C. U. Ranasinghe, Margaret A. Schwarz
Biochemical Pharmacology (2022) Vol. 204, pp. 115245-115245
Closed Access | Times Cited: 11
Recent advances in developing degraders & inhibitors of lysine methyltransferases
Julia Velez, H. Ümit Kanıskan, Jian Jin
Current Opinion in Chemical Biology (2023) Vol. 76, pp. 102356-102356
Open Access | Times Cited: 6
Targeting LC3/GABARAP for degrader development and autophagy modulation
Martin P. Schwalm, Johannes Dopfer, Adarsh Kumar, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 6
PROTAC degraders of the METTL3-14 m6A-RNA methyltransferase
Francesco Errani, Annalisa Invernizzi, Marcin Herok, et al.
(2024)
Open Access | Times Cited: 1
Discovery of PRMT3 Degrader for the Treatment of Acute Leukemia
Wanyi Zou, Mengna Li, Shili Wan, et al.
Advanced Science (2024) Vol. 11, Iss. 38
Open Access | Times Cited: 1
Critical assessment of LC3/GABARAP ligands used for degrader development and ligandability of LC3/GABARAP binding pockets
Martin P. Schwalm, Johannes Dopfer, Adarsh Kumar, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top